Issue Type: Payer and Supply Chain Economics Favor Higher Cost Drugs

in challenge narrative

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • Supply Chain Economics Favor Higher Cost Drugs

  • Who Is Sowing Seeds of Confusion About The QALY?

  • Mortgaging New Treatments Kicks the Can on High Drug Prices

  • 60 Minutes: The Rockford File

    60 Minutes: The Rockford File

  • TEDMED Talk: Changing the Drug Pricing Game with Dr. Peter Bach

  • DPL and Collaborators to Publish Drug Pricing Primer Series

  • A Q&A with Peter Bach

  • The Insurance Companies’ Latest Target: Specialty Drugs